Compare BridgeBio Pharma Inc (BBIO) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marathon Digital Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Marathon Digital Holdings Inc trades at $9.91 (market cap $3.69B). The key difference: BridgeBio Pharma Inc is far larger — about 4.5× Marathon Digital Holdings Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | MARA | |
|---|---|---|
Market Cap | $16.61B | $3.69B |
Sector | Health | Technology |
52-Week High | $90.17 | $22.84 |
52-Week Low | $47.29 | $6.73 |
Enterprise Value | $18.16B | $5.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
MARA Holdings trades at $10.09, down 5.26% amid a bearish technical signal and recent earnings misses. The stock faces fundamental pressure with a net income margin of -429.71% for 2026 and negative cash flow from operations. Despite this, analyst consensus remains optimistic with a $16.08 price target, and the company is pivoting its power infrastructure toward AI compute to complement Bitcoin mining.
The outlook is mixed; the high analyst buy rating and strategic pivot offer potential upside, but persistent losses, negative cash flow, and Bitcoin market volatility pose significant risks. Investor sentiment is cautious following Q2 2026 results, with the stock trading well below its 52-week high, highlighting both opportunity and substantial downside exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
